-+ 0.00%
-+ 0.00%
-+ 0.00%

Novo Gains Exclusive Global License to Nanexa's PharmaShell Platform via EUR1.17 Billion Deal

MT Newswires·09/24/2026 23:31:04
Listen to the news
11:31 PM EDT, 09/24/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) secured the global exclusive license to use Nanexa's (NANEXA.ST) PharmaShell atomic layer deposition drug delivery technology platform for total payments of up to 1.165 billion euros, according to a Thursday release. Under the licensing and collaboration deal, the Danish drugmaker may use the platform for certain therapeutic peptide drugs for obesity, type 2 diabetes and other cardiometabolic diseases. The deal covers up to five development programs. Nanexa will receive an upfront payment of 615 million euros and additional consideration, subject to certain development, regulatory, and sales milestones. It is also entitled to low single-digit royalties on global net sales.